NextTrip, Inc. (NTRP)
(Delayed Data from NSDQ)
$2.55 USD
-0.16 (-5.90%)
Updated May 3, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Petros Pharmaceuticals, Inc. [NTRP]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Healthcare: Coverage Update
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
We are transferring coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Clinical Progress Continues as 2Q18 Financial Results Reported
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
AAIC Data Details Bryostatin Mechanism of Action and Exclusion Criteria
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Scientific Advisory Board Adds World Renowned Academic And Clinical Experts
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Confirmatory Phase 2 Study Design Is Consistent With Our Expectations
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Initiating Coverage on Companies with Novel Approaches to Alzheimer''s Disease
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Initiating Coverage with Buy Rating
Provider: Roth Capital Partners, Inc.
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Petros Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: NAPODANO J